CCL2 and monocytic leukemia: LPS treatment upregulated LINC01270 in the human monocytic leukemia cell line THP-1, and its suppression via siRNA enhanced NF-κB activity and the production of pro-inflammatory cytokines IL-6, IL-8, and MCP-1.